Anika Therapeutics (NASDAQ:ANIK – Get Free Report) and MediWound (NASDAQ:MDWD – Get Free Report) are both small-cap healthcare companies, but which is the superior investment? We will compare the two companies based on the strength of their risk, institutional ownership, dividends, analyst recommendations, valuation, profitability and earnings.
Institutional and Insider Ownership
91.5% of Anika Therapeutics shares are owned by institutional investors. Comparatively, 46.8% of MediWound shares are owned by institutional investors. 12.1% of Anika Therapeutics shares are owned by insiders. Comparatively, 9.2% of MediWound shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.
Profitability
This table compares Anika Therapeutics and MediWound’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Anika Therapeutics | -1.43% | 1.87% | 1.39% |
| MediWound | -234.98% | -58.44% | -29.62% |
Risk & Volatility
Anika Therapeutics has a beta of 0.21, indicating that its share price is 79% less volatile than the S&P 500. Comparatively, MediWound has a beta of 0.07, indicating that its share price is 93% less volatile than the S&P 500.
Analyst Ratings
This is a breakdown of recent ratings and target prices for Anika Therapeutics and MediWound, as reported by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Anika Therapeutics | 1 | 1 | 2 | 0 | 2.25 |
| MediWound | 1 | 0 | 4 | 0 | 2.60 |
Anika Therapeutics currently has a consensus price target of $22.00, indicating a potential upside of 64.18%. MediWound has a consensus price target of $33.00, indicating a potential upside of 155.81%. Given MediWound’s stronger consensus rating and higher probable upside, analysts clearly believe MediWound is more favorable than Anika Therapeutics.
Earnings and Valuation
This table compares Anika Therapeutics and MediWound”s gross revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Anika Therapeutics | $112.82 million | 1.59 | -$10.88 million | ($0.13) | -103.08 |
| MediWound | $16.96 million | 9.90 | -$23.88 million | ($1.80) | -7.17 |
Anika Therapeutics has higher revenue and earnings than MediWound. Anika Therapeutics is trading at a lower price-to-earnings ratio than MediWound, indicating that it is currently the more affordable of the two stocks.
Summary
Anika Therapeutics beats MediWound on 9 of the 14 factors compared between the two stocks.
About Anika Therapeutics
Anika Therapeutics is a medical technology company focused on orthopedic care and regenerative medicine. Founded in 1992 and headquartered in Bedford, Massachusetts, the company develops products using hyaluronic acid, a substance found naturally in the body and used in treatments for joint and tissue conditions. Its products include Orthovisc and Monovisc, injectable hyaluronic acid treatments for knee osteoarthritis. Anika also offers orthopedic products for areas such as sports medicine, joint preservation, and bone repair, including its Tactoset bone-void filler.
About MediWound
MediWound Ltd. is an Israeli biotechnology company that develops topical enzymatic treatments for tissue repair. Its products are designed to remove damaged tissue and support care for patients with burns and chronic wounds. The company’s lead product, NexoBrid, is a bromelain-based treatment used to remove dead tissue from deep thermal burns. It has received regulatory approvals in the United States and other markets. In the United States, MediWound works with Vericel to commercialize the product.
Receive News & Ratings for Anika Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Anika Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
